ECSP18038867A - Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico h4 (h4) - Google Patents
Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico h4 (h4)Info
- Publication number
- ECSP18038867A ECSP18038867A ECIEPI201838867A ECPI201838867A ECSP18038867A EC SP18038867 A ECSP18038867 A EC SP18038867A EC IEPI201838867 A ECIEPI201838867 A EC IEPI201838867A EC PI201838867 A ECPI201838867 A EC PI201838867A EC SP18038867 A ECSP18038867 A EC SP18038867A
- Authority
- EC
- Ecuador
- Prior art keywords
- methods
- compositions
- ultrapure
- preparation
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente solicitud se refiere a composiciones ultrapuras que contienen dihidrato de N4(ciclopropilmetil)6[(3R)3(metilamino)pirrolidin1il]pirimidin2,4diamina tartrato, métodos para su elaboración, formulaciones que las contienen, métodos para usarlas para tratar enfermedades y afecciones mediadas por H4 y formas alternativas de sal de las mismas
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562246482P | 2015-10-26 | 2015-10-26 | |
US201662329091P | 2016-04-28 | 2016-04-28 | |
US201662359066P | 2016-07-06 | 2016-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP18038867A true ECSP18038867A (es) | 2018-05-31 |
Family
ID=57200025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI201838867A ECSP18038867A (es) | 2015-10-26 | 2018-05-21 | Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico h4 (h4) |
Country Status (21)
Country | Link |
---|---|
US (2) | US20170158671A1 (es) |
EP (1) | EP3368528A1 (es) |
JP (1) | JP2018531288A (es) |
KR (1) | KR20180067683A (es) |
CN (1) | CN108602801A (es) |
AU (2) | AU2016344627B9 (es) |
BR (1) | BR112018007765A2 (es) |
CA (1) | CA3001636A1 (es) |
CL (1) | CL2018001092A1 (es) |
CO (1) | CO2018004323A2 (es) |
EC (1) | ECSP18038867A (es) |
HK (1) | HK1252050A1 (es) |
IL (1) | IL258813A (es) |
MX (1) | MX2018005140A (es) |
PE (1) | PE20181364A1 (es) |
PH (1) | PH12018500822A1 (es) |
RU (1) | RU2018119104A (es) |
SG (1) | SG11201802676QA (es) |
TW (1) | TW201729810A (es) |
WO (1) | WO2017072131A1 (es) |
ZA (1) | ZA201802183B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
CA2935960C (en) | 2014-01-08 | 2023-01-10 | Bart Lipkens | Acoustophoresis device with dual acoustophoretic chamber |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
WO2019073388A1 (en) * | 2017-10-09 | 2019-04-18 | Teva Pharmaceutical Industries Ltd. | NEW SALT AND FORMS IN THE STRONG STATE OF ESCITALOPRAM |
BR112020009889A2 (pt) | 2017-12-14 | 2020-11-03 | Flodesign Sonics, Inc. | acionador e controlador de transdutor acústico |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072548A2 (en) | 2001-03-09 | 2002-09-19 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic compounds and their use as histamine h4 ligands. |
DE60305052T2 (de) | 2002-09-06 | 2006-12-21 | Janssen Pharmaceutica N.V. | Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden |
KR101235116B1 (ko) * | 2005-10-17 | 2013-02-20 | 에스케이케미칼주식회사 | 광학활성 암로디핀 겐티세이트 염의 제조방법 |
NL2000323C2 (nl) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
JP2008127359A (ja) * | 2006-11-22 | 2008-06-05 | Kowa Co | アトピー性皮膚炎の予防及び/又は治療剤 |
US9688989B2 (en) * | 2012-06-08 | 2017-06-27 | Sensorion | H4 receptor inhibitors for treating tinnitus |
-
2016
- 2016-10-24 TW TW105134313A patent/TW201729810A/zh unknown
- 2016-10-25 US US15/333,713 patent/US20170158671A1/en not_active Abandoned
- 2016-10-25 US US15/770,825 patent/US20190135787A1/en not_active Abandoned
- 2016-10-25 KR KR1020187014495A patent/KR20180067683A/ko unknown
- 2016-10-25 RU RU2018119104A patent/RU2018119104A/ru not_active Application Discontinuation
- 2016-10-25 EP EP16785505.5A patent/EP3368528A1/en not_active Withdrawn
- 2016-10-25 AU AU2016344627A patent/AU2016344627B9/en not_active Ceased
- 2016-10-25 PE PE2018000602A patent/PE20181364A1/es unknown
- 2016-10-25 SG SG11201802676QA patent/SG11201802676QA/en unknown
- 2016-10-25 CA CA3001636A patent/CA3001636A1/en not_active Abandoned
- 2016-10-25 CN CN201680076200.2A patent/CN108602801A/zh active Pending
- 2016-10-25 JP JP2018540217A patent/JP2018531288A/ja active Pending
- 2016-10-25 MX MX2018005140A patent/MX2018005140A/es unknown
- 2016-10-25 WO PCT/EP2016/075708 patent/WO2017072131A1/en active Application Filing
- 2016-10-25 BR BR112018007765A patent/BR112018007765A2/pt not_active Application Discontinuation
-
2018
- 2018-04-04 ZA ZA2018/02183A patent/ZA201802183B/en unknown
- 2018-04-17 PH PH12018500822A patent/PH12018500822A1/en unknown
- 2018-04-18 IL IL258813A patent/IL258813A/en unknown
- 2018-04-24 CO CONC2018/0004323A patent/CO2018004323A2/es unknown
- 2018-04-25 CL CL2018001092A patent/CL2018001092A1/es unknown
- 2018-05-21 EC ECIEPI201838867A patent/ECSP18038867A/es unknown
- 2018-09-05 HK HK18111382.3A patent/HK1252050A1/zh unknown
-
2020
- 2020-02-06 AU AU2020200840A patent/AU2020200840A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2018001092A1 (es) | 2018-08-10 |
SG11201802676QA (en) | 2018-05-30 |
CA3001636A1 (en) | 2017-05-04 |
AU2016344627B2 (en) | 2019-11-07 |
EP3368528A1 (en) | 2018-09-05 |
RU2018119104A (ru) | 2019-11-28 |
BR112018007765A2 (pt) | 2018-10-23 |
AU2016344627A1 (en) | 2018-05-10 |
CN108602801A (zh) | 2018-09-28 |
IL258813A (en) | 2018-06-28 |
JP2018531288A (ja) | 2018-10-25 |
PE20181364A1 (es) | 2018-08-27 |
HK1252050A1 (zh) | 2019-05-10 |
RU2018119104A3 (es) | 2020-02-19 |
CO2018004323A2 (es) | 2018-07-19 |
KR20180067683A (ko) | 2018-06-20 |
US20170158671A1 (en) | 2017-06-08 |
PH12018500822A1 (en) | 2018-10-01 |
AU2020200840A1 (en) | 2020-02-27 |
TW201729810A (zh) | 2017-09-01 |
AU2016344627B9 (en) | 2019-11-28 |
MX2018005140A (es) | 2018-05-07 |
WO2017072131A1 (en) | 2017-05-04 |
US20190135787A1 (en) | 2019-05-09 |
ZA201802183B (en) | 2019-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP18038867A (es) | Composiciones de pirimidina, composiciones ultrapuras y sales de las mismas, métodos su elaboración y métodos para su uso en el tratamiento de enfermedades y afecciones mediadas por el receptor histamínico h4 (h4) | |
CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
CO2017005483A2 (es) | Forma cristalina de sulfato de hidrógeno de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1- il)-pirazol[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida | |
BR112015020118A2 (pt) | derivados de 2-aminopirimidina para o tratamento de infecções virais | |
EA201690093A1 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
EA201991767A1 (ru) | Производные пурина для лечения вирусных инфекций | |
DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
UY35369A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
DOP2018000065A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer | |
EA201690303A1 (ru) | ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНОВ ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ | |
BR112015010663A8 (pt) | formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo | |
EA201590663A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
CL2020001762A1 (es) | Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464) | |
AR100215A1 (es) | Conjugados de anticuerpo-fármaco anti-ptk7 | |
CL2019000485A1 (es) | Uso de pridopidina para el tratamiento de la disminución funcional. | |
CL2018002807A1 (es) | Métodos de tratamiento de cánceres pediátricos. | |
PE20150637A1 (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
CL2014000932A1 (es) | Polimorfos cristalinos de n4-(4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-3-metilfenil)-n6-(4,4-dimetil-4,5-dihidrooxazol-2-il)quinazolina-4,6-diamina, inhibidores de erbb2; procedimiento para prepararlos; composicion farmaceutica; metodo para prevenir o tratar; y uso para tratar el cancer de mama, gastrico y biliar, entre otros. | |
NI201600176A (es) | Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer. | |
CL2018003421A1 (es) | Combinaciones farmacéuticas. | |
EA201690323A1 (ru) | Способы лечения заболеваний уха у детей | |
CL2017000223A1 (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
CO2018012180A2 (es) | Métodos de tratamiento para enfermedades colestásicas y fibróticas | |
CL2016001421A1 (es) | Derivados de [1,2,4] triazolo [1,5-a] pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias como la leishmaniasis. |